SPONTAN® Phase II interim data demonstrates rapid onset and pharmacokinetic profile addressing FDA Pre-IND requirements across adult and ≥65 populations

---
SPONTAN® Phase II interim data demonstrates rapid onset and pharmacokinetic profile addressing FDA Pre-IND requirements across adult and ≥65 populations
Vote:
0 0
Previous Blueport Acquisition Ltd and SingAuto Inc Announce Business Combination Agreement to Create a Publicly Listed Company
Next TEN-YEAR PIVOTAL DATA REINFORCE THE LONG-TERM DURABILITY OF EDWARDS' RESILIA TISSUE

Related News

BrightGene Announces Positive Topline Phase 1 Results of Oral BGM0504 in Obesity in China and the United States

Createrna Announces Positive Top-Line Results from Phase 1 Clinical Trials of QR052107B Tablet in Healthy Volunteers

PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients.

Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab)

Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib in Moderate-to-Severe Atopic Dermatitis

GenFleet Therapeutics to Present Phase I Data for GFH312 at 2023 American Society for Clinical Pharmacology & Therapeutics Meeting

menu
menu